期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 147, 期 2, 页码 510-+出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2020.09.034
关键词
COPD; COVID-19; inhaled corticosteroids; viral infection
资金
- Wellcome Trust [WT096382AIA, 215275/Z/19/Z]
- British Society for Antimicrobial Chemotherapy
- National Institute for Health Research (NIHR)
- NIHR
- Imperial College
- NIHR Biomedical Research Centre
- MRC [G0800570, MR/P028225/1] Funding Source: UKRI
- Wellcome Trust [215275/Z/19/Z] Funding Source: Wellcome Trust
Inhaled corticosteroids (ICS) treatment in COPD patients reduces the expression of ACE2, the entry receptor for SARS-CoV-2, potentially contributing to a reduced risk of COVID-19 infection in these patients.
Background: The mechanisms underlying altered susceptibility and propensity to severe Coronavirus disease 2019 (COVID-19) disease in at-risk groups such as patients with chronic obstructive pulmonary disease (COPD) are poorly understood. Inhaled corticosteroids (ICSs) are widely used in COPD, but the extent to which these therapies protect or expose patients to risk of severe COVID-19 is unknown. Objective: The aim of this study was to evaluate the effect of ICSs following pulmonary expression of the SARS-CoV-2 viral entry receptor angiotensin-converting enzyme-2 (ACE2). Methods: We evaluated the effect of ICS administration on pulmonary ACE2 expression in vitro in human airway epithelial cell cultures and in vivo in mouse models of ICS administration. Mice deficient in the type I IFN-a/b receptor (Ifnar12/2) and administration of exogenous IFN-b were used to study the functional role of type-I interferon signaling in ACE2 expression. We compared sputum ACE2 expression in patients with COPD stratified according to use or nonuse of ICS. Results: ICS administration attenuated ACE2 expression in mice, an effect that was reversed by exogenous IFN-b administration, and Ifnar12/2 mice had reduced ACE2 expression, indicating that type I interferon contributes mechanistically to this effect. ICS administration attenuated expression of ACE2 in airway epithelial cell cultures from patients with COPD and in mice with elastase-induced COPDlike changes. Compared with ICS nonusers, patients with COPD who were taking ICSs also had reduced sputum expression of ACE2. Conclusion: ICS therapies in COPD reduce expression of the SARS-CoV-2 entry receptor ACE2. This effect may thus contribute to altered susceptibility to COVID-19 in patients with COPD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据